GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
75.88
+1.66 (+2.24%)
At close: 4:00PM EST

76.00 +0.12 (0.16%)
After hours: 7:48PM EST

Stock chart is not supported by your current browser
Previous Close74.22
Open74.60
Bid75.20 x 2000
Ask76.92 x 100
Day's Range74.39 - 76.27
52 Week Range63.76 - 86.27
Volume9,179,903
Avg. Volume8,217,248
Market Cap99.12B
Beta0.89
PE Ratio (TTM)8.64
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.08 (2.80%)
Ex-Dividend Date2017-12-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta
    Zacks4 hours ago

    Gilead (GILD) Posts Updated Data on CAR-T Therapy Yescarta

    Gilead (GILD) announced follow-up data from a phase II study, on its CAR-T therapy, Yescarta for treatment of refractory large B-cell lymphoma.

  • What's Causing Juno Therapeutics Shares to Tumble 11.9% Today
    Motley Fool8 hours ago

    What's Causing Juno Therapeutics Shares to Tumble 11.9% Today

    Investors are selling shares following an important presentation at a key industry conference.

  • Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today
    Zacks10 hours ago

    Here's Why Bluebird Bio (BLUE) Stock Skyrocketed Today

    Shares of Bluebird Bio (BLUE) were up nearly 20% in early morning trading Monday as investors responded to the company's announcement that its CAR-T candidate, bb2121, produced encouraging results in patients with a deadly blood cancer.

  • Company News For Dec 11, 2017
    Zacks12 hours ago

    Company News For Dec 11, 2017

    Companies in the news are: GILD,AOBC,UNFI,UAL

  • Barrons.com12 hours ago

    Gilead Sciences: Better Data, Better Stock?

    Shares of Gilead Sciences (GILD) are higher on Monday, building on its strength from Friday when it announced its acquisition of Cell Design Labs. Gilead got a boost today from its its presentation at the American Society of Hematology's (ASH) annual meeting, where it and other companies provided update on their CAR-T therapies aimed at cancer. BMO Capital Markets' M. Ian Somaiya wrote that the news was good for Gilead and its peers: Updates from the three leading trials of CD-19 CAR-T therapy in DLBCL (GILD's Yescarta, Juno Therapeutics' (JUNO) JCAR017, Novartis' (NVS) Kymriah) raise the bar yet again for CAR-Ts.

  • MarketWatchyesterday

    Republican tax bill makes big winners of Amgen, Gilead and other drugmakers

    Of all U.S. companies, drugmakers have some of the most cash held outside the country.

  • Is Gilead Sciences, Inc. a Buy?
    Motley Foolyesterday

    Is Gilead Sciences, Inc. a Buy?

    The answer is a definite...

  • Reutersyesterday

    Gilead's new drug keeps 56 pct of lymphoma trial patients alive

    More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results presented on Sunday. Yescarta, approved by the U.S. Food and Drug Administration in October for aggressive large B-cell lymphoma that did not respond to other treatments, is part of a new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, designed to reprogram the body's own immune cells to recognize and attack malignant cells. Follow-up on 108 patients treated with Yescarta showed that 42 percent remained in remission after a median of 15 months, and 56 percent were still alive, according to research presented in Orlando at the annual meeting of the American Society of Hematology.

  • Capital Cube3 days ago

    ETFs with exposure to Gilead Sciences, Inc. : December 8, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Gilead Sciences, Inc. Here are 5 ETFs with the largest exposure to GILD-US. Comparing the performance and risk of Gilead Sciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Barrons.com3 days ago

    Gilead Sciences: Look Who's Shopping!

    Shares of Gilead Sciences (GILD) are higher Friday, after it announced its acquisition of Cell Design Labs. Kite Pharma, which Gilead bought earlier this year, already owned some 12% of the firm, so Gilead ...

  • Why Biotech Stocks May Wait A While Before Feeling The Love
    Investor's Business Daily3 days ago

    Why Biotech Stocks May Wait A While Before Feeling The Love

    Beleaguered biotech investors will likely have to wait until 2018 to get some much-needed relief, analysts say.

  • Gilead Sciences to Acquire Cell Design Labs for $567 Million
    Zacks4 days ago

    Gilead Sciences to Acquire Cell Design Labs for $567 Million

    Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

  • Reuters4 days ago

    Gilead to buy Cell Design Labs for up to $567 mln

    Drugmaker Gilead Sciences Inc said on Thursday it was acquiring privately-held Cell Design Labs Inc for up to $567 million, giving it access to new technology platforms that would help in the development of cancer drugs. The deal strengthens Gilead's focus on CAR-T drugs, a new class of cancer therapies that involve genetically modifying a patient's own immune cells to better recognize and attack cancer. Gilead said it would make an initial upfront payment to Cell Design of about $175 million and additional payments of up to $322 million upon meeting certain milestones.

  • Biopharma wins in Trump tax bill
    Yahoo Finance Video8 hours ago

    Biopharma wins in Trump tax bill

    One sector that's poised to win big in the Trump tax bill, biopharma. Yahoo Finance's Seana Smith, Andy Serwer and Melody Hahm discuss.